Literature Analysis of Adverse Effects Induced by Sunitinib

Abstract

Objective To analyze adverse drug reactions (ADR) caused by sunitinib and provide reference for clinical safety. Methods The case reports of ADR related to sunitinib in six Chinese and English databases from 2006 to 2021 were searched to extract relevant data, and then statistical analysis was performed. Results and Conclusion A total of 147 articles were included, involving 156 cases and 283 adverse events. Adverse reactions occurred at the highest rate after 31 to 180 days of drug administration, and ADR involved organs/systems mainly in blood and lymphatic disorders (17.67%), gastrointestinal disorders (15.55%), and skin and subcutaneous tissue disorders (10.60%). The adverse effects caused by sunitinib involve multiple organs/systems throughout the body. Besides, there are many severe fatal cases. During clinical medication, patients should be monitored regularly, and drugs should be reduced or stopped timely when adverse reactions occur to reduce the risk of clinical medication.

Keywords

sunitinib / adverse drug reaction (ADR) / literature analysis

References

[1] Jain R, Mathew P, Wood CG, et al. Sunitinib-induced acute hemolysis without hypertension: A case report[J]. Clinical Genitourinary Cancer, 2008, 6: 122-123.

[2] Mutlu H, Buyukcelik A, Akca Z, et al. Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor[J]. Journal of Oncology Pharmacy Practice, 2014, 20: 298-301.

[3] Sunitinib prescribing information[EB/OL]. (2022-03-01) [2023-02-01]. https://www.drugs.com/pro/sunitinib.html.

[4] Liao Binchi, Du Jing. Literature analysis of the adverse effects caused by sunitinib[J]. China Pharmacy, 2017, 28: 4932-4935.

[5] Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial[J]. Journal of Clinical Oncology, 2013, 31 (32): 4067-4075.

[6] Ready NE, Pang HMH, Gu L, et al. Chemotherapy with or without maintenance sunitinib for untreated extensivestage small-cell lung cancer: A randomized, doubleblind, placebo-controlled phase II study CALGB 30504 (Alliance)[J]. Journal of Clinical Oncology, 2015, 33 (15): 1660-1665.

[7] Vigil CE, Chiappori AA, Williams CA, et al. Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas[J]. Journal of Clinical Oncology, 2008, 26: 10535-10537.

[8] Li Jia, Jin Xuejun, Wang Hui, et al. One case of severe thrombocytopenia and hypothyroidism caused by sunitinib[J]. Chinese Journal of New Drugs and Clinical Remedies, 2016, 35 (7): 522-524.

[9] Reed JP, Chung J, Banerjee N. A case of cobalamin deficiency and macrocytic anemia secondary to sunitinib[J]. Cureus Journal of Medical Science, 2019, 11 (3): e4310.

[10] Pierce GF, Mustoe TA, Lingelbach J, et al. Plateletderived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms[J]. Journal of Cell Biology, 1989, 109: 429-440.

[11] Li Mingqing, Srinivas S. Acute pancreatitis associated with sorafenib[J]. Southern Medical Journal, 2007, 100: 909-911.

[12] Hur H, Park AR, Jee SB, et al. Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment[J]. World Journal of Gastroenterology, 2008, 14 (39): 6096-6099.

[13] Deng Bo, Jia liqun, Li Ling. Progress in hand-foot syndrome caused by targeted therapeutic drug multikinase inhibitors[J]. Chinese Pharmaceutical Journal, 2010, 45 (23): 1793-1796.

[14] Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome[J]. New England Journal of Medicine, 1996, 334: 494-500.

[15] Nott L, Price TJ, Pittman K, et al. Hyperammonemia encephalopathy: An important cause of neurological deterioration following chemotherapy[J]. Leuk Lymphoma, 2007, 48: 1702-1711.

[16] Aparicio-Gallego G, Blanco M, Figueroa A, et al. New insights into molecular mechanisms of sunitinib-associated side effects[J]. Molecular Cancer Therapeutics, 2011, 10: 2215-2223.

[17] Manir KS, Banerjee D, Bhowmick R, et al. Sunitinibinduced acute severe hypothyroidism in a case of metastatic gastrointestinal stromal tumor: A case report[J]. Journal of Cancer Research and Therapeutics, 2018, 14: S818-S819.

[18] Liu YC, Chang PMH, Liu CY, et al. Sunitinib-induced nephrotic syndrome in association with drug response in a patient with Xp11.2 translocation renal cell carcinoma[J]. Japanese Journal of Clinical Oncology, 2011, 41: 1277- 1281.

[19] Gomez-Abuin G, Karam AA, Mezzadri NA, et al. Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib[J]. Clinical Genitourinary Cancer, 2009, 7 (1): 62-63.

[20] Fleissig Y, Regev E, Lehman H. Sunitinib related osteonecrosis of jaw: A case report[J]. Oral Surgery Oral Medicine Oral Pathology Oral Radiology, 2012, 113: 1-3.